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Abstract
Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, usually arising after years
of chronic liver inflammation that could result from viral infections such as hepatitis B virus (HBV) and hepatitic C
virus (HCV) infections. Human cytomegalovirus (HCMV) infects primary human hepatocytes and remains an
important cause of morbidity in immunocompromised persons where it may manifest as symptomatic end-organ
disease including hepatitis. The goal of the present study was to determine a potential correlation between HCMV
infection and the appearance of HCC.
Methods: First, we analyzed the seroprevalence of HCMV in a cohort of 11,318 patients hospitalized between 2003
and 2009 in different departments of a French University Hospital. Second, we studied HCMV seroprevalence in a
cohort of 190 subjects who were stratified on the basis of age, gender, HCC, cirrhosis (Cir), and the exposition to
hepatotropic viruses (HCV, HBV). We further determined whether HCMV DNA was present specifically in tumour
area in liver biopsies from HCC-positive patients by using nested PCR.
Results: We found that the HCMV seroprevalence was high in the Hepatology department. The HCMV
seroprevalence was significantly higher in patients infected with HCV and/or HBV than in patients who were not
infected by those later viruses (76.2% versus 56.5%, p < 0.001). The HCMV seroprevalence was significantly higher
in patients with HCC (74%) and lower in patients without HCC (54% for HCC-/Cir+ patients, 57% for HCC-/Cir-
subjects). We observed a positive correlation between serum IL-6 levels and HCMV seroprevalence in cirrhotic
patients, but not in HCC patients. Serum IL-6 levels correlated positively with C-reactive protein (CRP) levels.
Preliminary histological studies from liver biopsies from HCC-positive patients highlighted that HCMV DNA can be
detected in tumour area of some of the patients studied.
Conclusions: Our results indicate that HCMV seroprevalence in patients with HCC is significantly higher than in
patients without HCC, is positively correlated with serum IL-6 levels in cirrhotic patients, and is positively associated
with the presence of other hepatotropic viruses such as HCV and HBV.
Background
Hepatocellular carcinoma (HCC) is the most common
primary liver cancer, usually arising after years of
chronic liver inflammation. Hepatitis B virus (HBV) and
hepatitis C virus (HCV) infections can lead to HCC,
whereas non-infectious inflammatory states, such as
chronic inflammation induced by alcohol consumption
and hereditary iron overload can also contribute to
HCC. IL-6 levels are elevated in the serum of patients
with all of these chronic liver diseases [1-3] and could
become even more elevated in those who develop HCC
[4-6]. Recently, obesity-promoted HCC development
was reported to depend on enhanced production of IL-6
which causes hepatic inflammation and activation of the
oncogenic factor STAT3 [7].
Human cytomegalovirus (HCMV) is an opportunistic,
species-specific herpesvirus that infects a large part of
the population worldwide and causes asymptomatic
latent infection in healthy subjects. However, it can
cause severe disease in the absence of an effective
immune response, especially in patients with AIDS and
in immunocompromised solid-organ and bone marrow
allograft recipients [8]. Histological and immunohisto-
chemical studies have demonstrated the presence of
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any medium, provided the original work is properly cited.infected cells in virtually all organs and the virus targets a
variety of cell types in vivo, including macrophages,
endothelial cells, epithelial cells, fibroblasts, stromal cells,
neuronal cells smooth muscle cells, and hepatocytes
[9,10]. Blood monocytes and tissue macrophages are
believed to serve as target cells in infected organs, acting
as viral disseminators throughout the host or as sites of
HCMV latency [11]. Elevated levels of IL-6 have been
reported to accompany HCMV replication in transplanted
lungs and bone marrow during episodes of inflammation
or rejection [12,13]. IL-6 mRNA expression is upregulated
by HCMV infection in the absence of de novo expression
of viral genes [14-17]. Virion binding activates multiple
intracellular signal transduction pathways, including the
phosphatidylinositol kinase, MAPK/ERK and protein
kinase C pathways, all of which lead to the activation of
nuclear factors such as NF-kB and p38 [18,19], which are
known inducers of IL-6 gene transcription [20].
In the present study, the seroprevalence of HCMV
and the IL-6 production were determined in patients
hospitalized who were studied on the basis of HCC, cir-
rhosis and the presence or not of hepatotropic viruses.
Methods
Study population and setting
To determine the seroprevalence of HCMV in the depart-
ments of the Besancon University Hospital, serum samples
were collected for routine serological HCMV diagnostics
performed at the Department of Medical Virology, Besan-
con University Hospital, Besançon, France. The samples
were obtained from 11,318 patients hospitalized between
2003 and 2009. We analyzed the data retrospectively con-
sidering every patient only once. In addition, fifty adult
patients with HCC and cirrhosis, 41 adult patients with
cirrhosis but no HCC, and 99 patients with neither HCC
nor cirrhosis were eligible for enrolment at the Besancon
University Hospital. These patients included a cohort of
92 patients who were participating in studies that assessed
HCMV serological analysis, the measurement of serum
IL-6 and C-reactive protein (CRP), and clinical outcome.
The seroprevalence of HCV, HBV, and HIV was also mea-
sured in each serum.
The study was in accordance with ethical principles as
formulated in the World Medical Association Declara-
tion of Helsinki.
Study design
Patients were followed up with use of HCMV serological
analysis, HCV, HBV, and HIV serological analysis, the
measurement of serum IL-6 and CRP levels and clinical
outcome.
HCMV, HBV, HCV and HIV serodiagnostic
Serum samples were assessed for anti-HCMV IgG and
IgM antibodies with use of an ELISA (Elisa Biotest, Liai-
son Diasorin). Serum samples were also assessed for
anti-HCV IgG, HBs Ag, anti-HBs IgG, anti-HBcore IgG
and anti-HIV Ig (Axsym).
Measurement of serum IL-6 and CRP
IL-6 and CRP were measured in the serum of patients
using ELISA kit and immunochemistry (R&D systems
and Image Beckman Coulter, respectively).
Histological data
Liver biopsies from 3 patients diagnosed as hepatocellu-
lar carcinoma in the Besancon University Hospital were
considered for this study. For each patient, the patholo-
gist selected one biopsy in a “tumour area” and another
biopsy in a “safe area”. All specimens were obtained in
paraffin blocks. Prior to DNA extraction, paraffin-
embedded specimens were treated with xylene during 5
minutes under agitation and ethanol during 5 minutes
under agitation. DNA was extracted and purified using
QIAamp kit (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. The DNA extracted from
the liver biopsy was quantified in spectrophotometer. A
total of 200 ng DNA was used for performing first PCR
reaction using full length primers of UL82 (pp71). After
initial heating step at 94 for 5 minutes, the thermal
cycling protocol was as follows: 1 min at 94°C, 1 min at
60°C and 1.5 min at 72°C for 35 cycles. 10 μlf r o mt h e
1 s tP C Rp r o d u c tw e r eu s e di nan e s t e d - P C Rp e r f o r m e d
using internal primers for UL82 (pp71) in slightly differ-
ent PCR Conditions: 45 sec at 94°C, 1 min at 60°C and
45 sec at 72°C for 35 cycles. Nested amplification pro-
ducts were visualized on 1% agarose gel electrophoresis
and stained with ethidium bromide. The sequences of
the primers used were 5’-TAGATGCGGGGTCG
ACTGCGT-3’ and 5’-TCAGGCATCGTCCTCGCC
CGG-3’ for the UL82 (pp71) full length and 5’-CG
AAAGCATTCTGGATCTGC-3’ and 5’-TTTCTGCAT
CACGACTCACC-3’ for the UL82 (pp71) internal
length.
Statistical analysis
Values are the means and SDs of independent experi-
ments. Statistical analysis was performed by student’sT
test, chi-square and logistic regression for multivariate
analyses of factors associated with CMV seropositivity
and HCC, and differences were considered significant at
a value of p < 0.05. Microsoft Excel was used to con-
struct the plots.
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High HCMV seroprevalence in several departments
including the Hepatology department
To assess the HCMV seroprevalence among patients
hospitalized in the Besancon University Hospital and to
compare the HCMV seroprevalence between the differ-
ent hospital departments, serum samples were collected
for routine serological HCMV diagnostics performed at
the Department of Medical Virology, Besancon Univer-
sity Hospital. The samples were obtained from 11,318
patients hospitalized between 2003 and 2009. We ana-
lyzed the data retrospectively considering every patient
at least once; hence the number of samples tested is
12,889 (see Additional File 1, Table S1). The HCMV
seroprevalence was 50.73% (95%CI: 49.81-51.65) with a
mean age of 45.13 years (95%CI: 44.69-45.57). We
observed a positive correlation between the age and the
HCMV seroprevalence (r
2 =0 . 6 1 6 )w i t haw e a kH C M V
seroprevalence in pediatric and neonatal populations
(20.32% and 38.09%, respectively). Among the depart-
ments with the highest HCMV prevalence were the Der-
matology Department (74.84%), the Urology/Nephrology
Department (69.16%), the Infectious Diseases Depart-
ment (63.81%) and the Hepatology Department (71.88%)
(see Additional File 1, Table S1). Among outclinic
patients hospitalized in the Dermatology Department
and in the Infectious Diseases Department 77.02% and
56.19% respectively, were infected with HIV. The
HCMV seroprevalence among patients hospitalized in
these two Departments was significantly higher in HIV-
positive patients than in HIV-negative patients with
83.06% versus 47.30% (p < 0.001) in the Dermatology
Department and 84.75% versus 36.96% (p < 0.001) in
the Infectious Diseases Department (Table 1). Among
patients of the Hepatology Department, infection with
HCV and/or HBV was observed in 36.77% of the
patients. The HCMV seroprevalence was significantly
higher in patients infected with HCV and/or HBV than
in patients who were not infected by those later viruses
(76.2% versus 56.5%, p < 0.001) (Table 2).
Higher HCMV seroprevalence in HCC-positive patients
Since we observed a high HCMV seroprevalence in the
Hepatology Department, we then focused our study on
50 adult patients with HCC and cirrhosis (HCC+), 41
adult patients with cirrhosis but no HCC (HCC-/Cir+),
and 99 patients with neither HCC nor cirrhosis (HCC-/
Cir-) who were eligible for enrolment at the Besancon
University Hospital. These patients included a cohort of
92 patients who were participating in studies that
assessed HCMV serological analysis, serum IL-6 and
CRP measurement, and clinical outcome. We matched
patients of each group for age and gender. Male subjects
were 87% of the patients and the mean age was 66
years.
HCMV seroprevalence was significantly increased in the
HCC+ group versus the HCC-/Cir+ and HCC-/Cir-
groups (74% versus 54% and 57%, respectively) (Figure 1).
Using unimodal statistical analysis, the HCMV seropreva-
lence was significantly higher in the HCC+ patients than
in the HCC-patients with 74% and 56%, respectively (p =
0.023) (Table 3, Figure 1). The HCMV seroprevalence was
not significantly higher in patients with cirrhosis or
infected with HCV, HBV or HIV (Table 3). By contrast,
HCC was significantly associated with HCV infection (p =
0.046) and always associated with cirrhosis (Table 3).
Using multimodal statistical analysis, the HCMV sero-
positivity was 3.45-fold more frequent in HCC+ patients
(OR = 3.45; CI95%: 1.34-8.93; p = 0.010) and was inde-
pendent on the presence of cirrhosis or on infection
with HCV or HBV (Table 3). HCC was positively asso-
ciated with HCMV seropositivity (OR = 2.76, CI95%:
1.30-5.86, p = 0.008) (Table 3).
Systemic levels of IL-6, C-reactive protein, HCMV
seroprevalence and HCC
HCC development is dependent on enhanced produc-
tion of the tumor promoting cytokines such as IL-6
which causes hepatic inflammation and activation of the
oncogenic transcription factor STAT3 [7,21]. Therefore,
we measured serum IL-6 levels. High levels of serum IL-
6 were measured in both HCC+ and HCC-/Cir+ groups
(means of 8.53 and 8.34 pg/ml, respectively), but no sig-
nificant difference between the two groups was observed
(p = NS) (Figure 2A). Serum IL-6 levels were signifi-
cantly increased in the HCC+ and the HCC-/Cir+
groups versus healthy subjects (p < 0.05) (data not
shown). Interestingly, the serum IL-6 levels were higher
Table 1 HCMV seroprevalence and HIV infection in the Department of Dermatology and of Infectious Diseases
Department HIV Patients HCMV seropositivity (%) Age (years, mean)
Dermatology Positive 248 83.06 42.37
Negative 74 47.30 42.27
Infectious Diseases Positive 118 84.75 39.61
Negative 92 36.96 36.09
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(9.29 pg/ml versus 7.98 pg/ml), and the converse was
observed in HCC+ patients in whose decreased serum
IL-6 levels were measured in HCMV seropositive sub-
jects (Figure 2B). Increased serum IL-6 level was
observed in patients infected with hepatotropic viruses
(HBV and/or HCV) (8.99 versus 8.17 pg/ml, respec-
tively) (Figure 2C), or with HCV (9.63 versus 8.14 pg/
ml, respectively) (Figure 2D). Finally, serum IL-6 corre-
lated positively with that of CRP (r
2 = 0.49) (Figure 3).
Detection of HCMV DNA in the liver biopsies of some
HCC-positive patients
Liver biopsies from 3 HCC-positive patients were con-
sidered. For each patient, the pathologist selected
paraffin-embedded liver biopsy sample both from the
tumour area and the safe area. DNA was amplified by
nested PCR for HCMV pp71 (UL82)g e n e( F i g u r e4 ) .
Three different results were obtained. HCMV DNA was
specifically detected in liver tumour area (T) but not in
safe area (S) for one patient (patient 1). In the other
patients, HCMV DNA was either not detected (patient
3) or detected in both tumour area and safe area
(patient 2).
Discussion
We report here that HCMV seroprevalence in patients
with HCC is significantly higher than that of cirrhotic
patients without HCC. We observed a positive correla-
tion between HCMV seroprevalence and serum IL-6
Table 2 HCMV seroprevalence and HCV and/or HBV infection in the Department of Hepatology
Department Hepatology HCV and/or HBV Patients HCMV seropositivity (%) Age (years, mean)
Division 1 Positive 30 80.0 49.7
Negative 34 64.7 41.3
Division 2 Positive 49 81.6 58.5
Negative 99 58.6 57.4
Division 3 Positive 52 78.8 54.6
Negative 133 57.9 55.3
Total Positive 164 76.2 55.0
Negative 446 56.5 53.3
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Figure 1 HCMV seroprevalence in HCC+/Cir+, HCC-/Cir+, HCC-/Cir-subjects.
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Page 4 of 10levels in cirrhotic patients, but not in HCC patients. In
addition serum IL-6 levels correlated positively with
CRP levels. Our results question the role of HCMV in
the development of HCC.
H C M Vi sah i g h l yt r a n s m i s s i b l ea n dp r e v a l e n tb e t a
herpesvirus [22,23]. This pathogen is never cleared from
the body, persisting in a number of tissues via hypothe-
sized mechanisms including chronic productive infection
and/or latent infection with periodic subclinical reactiva-
tion [8,22]. Recently, HCMV has been linked to a variety
of chronic diseases with an inflammatory component
including cardiovascular disease [24], cognitive decline
including vascular dementia [25], functional impairment
[26] and cancer [27]. Although HCMV has been
reported as involved in hepatitis [28], its role in cancer
is just starting to emerge. The involvement of HCMV in
late inflammatory complications underscores its possible
role in inflammatory diseases and cancer. Evidence of
this involvement of HCMV in such phenomena is being
accumulated (review in: [27,29,30]. Early in vitro studies
suggested that HCMV was able to transform embryonic
fibroblasts in culture and to induce chromosomal
damages and mutations but HCMV has never been
accepted as oncogenic virus [27]. Later on the concept
of “oncomodulation” was proposed to explain the possi-
ble contribution of HCMV in tumour progression [31].
The oncomodulation states that HCMV infects the
tumour tissue and acts as a cofactor in amplifying
mechanisms of carcinogenesis without necessarily initi-
ating tumour. Support for this idea is based on experi-
ments showing that proteins of HCMV (or non-coding
RNAs) can influence the genesis and tumour growth
acting on the cell cycle, apoptosis, genetic instability,
invasiveness, angiogenesis, adhesion and cell migration.
These proteins have been the subject of extensive recent
reviews [27,32,33]. The increased sensitivity of detection
of HCMV in tumour tissues (immunohistochemistry, in
situ hybridization and PCR techniques) originally pro-
posed by Cobbs et al in 2002 served to highlight the
presence of HCMV proteins and DNA in tumour cells
but not in adjacent cells of several cancers such as
glioma [34], colon cancer [35], prostate cancer [36], and
some skin cancers [37]. Interestingly, the presence of
HCMV was also highlighted in the pre-cancerous
lesions such as colorectal polyps [35], and prostatic
intraepithelial neoplasia [36].
In order to determine the role of HCMV as a poten-
tial oncomodulator of HCC, we measured HCMV sero-
prevalence in patients with HCC, in cirrhotic patients
and HCC-/Cir- subjects. Our results clearly indicate that
HCMV seroprevalence is increased in patients with
HCC. Using multimodal statistical analysis, the HCMV
seropositivity was 3.45-fold more frequent in HCC+
patients and was independent on the presence of cirrho-
sis or on infection with HCV or HBV. Also, HCC was
positively associated with HCMV seropositivity and with
Table 3 Factors associated with HCC and with HCMV seropositivity
Unimodal analysis
HCMV associated factors
HCC Cirrhosis HCV HBV HIV Male gender Exposition to hepatotropic viruses
p 0.023 0.24 0.23 0.57 0.83 0.09 0.21
HCC associated factors
HCMV IgG+ Cirrhosis HCV HBV HIV Male Exposition to hepat. viruses
p 0.023 0 0.046 0.55 0.26 0.21 0.08
Multimodal analysis
HCMV associated factors
Odds Ratio CI95% p
HCC 3.45 1.34-8.93 0.010
Cirrhosis 0.71 0.31-1.62 0.418
Age > 65 years 0.59 0.31-1.14 0.119
Exposition to hepatotropic viruses 1.35 0.62-2.94 0.448
Male gender 0.43 0.15-1.24 0.118
HCC associated factors
IgG HCMV+ 2.76 1.30-5.86 0.008
Age > 65 years 1.48 0.73-2.98 0.278
Exposition to hepatotropic viruses 2.07 0.96-4.45 0.064
Male gender 2.80 0.84-9.30 0.093
Unimodal analysis and Multimodal analysis.
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Figure 2 Serum IL-6 levels in HCC+/Cir+ and HCC-/Cir+ groups: (A) without taking into account the virological status; (B) infected or not
with HCMV; (C) infected or not with hepatotropic viruses (HBV and/or HCV); (D) infected or not with HCV.
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Figure 3 Correlation between serum IL-6 and CRP.
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Page 6 of 10infection with HCV or HBV. These results suggest that
HCMV could be involved in the appearance of HCC, as
it is the case for HCV and HBV. To confirm this
hypothesis future studies will determine whether HCMV
genome and/or HCMV antigens can be detected in
hepatocytes of HCC patients. It is also possible that
high HCMV seroprevalence observed in HCC patients
and not in cirrhotic patients could result from HCMV
infection of vessels of the liver and/or from infected cir-
culating monocytes arriving at sites of liver inflamma-
tion [9,38].
We also observed a positive correlation between
HCMV seroprevalence and serum IL-6 levels in cirrho-
tic patients, but not in HCC patients. Increased serum
IL-6 levels have been reported in cirrhotic patients and
HCC patients infected with HBV and HCV [39-41].
Nevertheless, serum IL-6 levels in HCC patients depend
on the virus involved (HBV versus HCV), the genotype
of the virus especially for HCV and ultimately from the
IL-6 gene polymorphism [42-45]. Elevated levels of IL-6
have been reported to accompany HCMV replication in
transplanted lungs and bone marrow during episodes of
inflammation or rejection [12,13]. IL-6 mRNA expres-
sion is up-regulated by HCMV infection [15-17] and
increased IL-6 levels are a critical factor involved in
inflammation and carcinogenesis, especially in liver [7].
IL-6 production has been detected in many cell types,
however the primary sources of the cytokine are mono-
cytes and macrophages at sites of inflammation during
acute inflammation, as well as T cells in chronic inflam-
mation. In homeostatic conditions, IL-6 levels are low,
whereas under stress conditions, amounts of IL-6 rise
quickly in the serum. Production of IL-6 depends on
several transcription factors, primarily NF-kB, C/EBPb
(formerly NF-IL6) and AP-1 [46]. The stimuli that trig-
ger activation of these transcription factors include
TNFa and IL-1, bacterial products (LPS) or viral
infections such as HIV, HCV and HCMV [47-49]. After
IL-6 is secreted from the activated monocyte or macro-
phage, it can act on other cells locally or systemically. In
classical IL-6 signaling, the cytokine engages its receptor
IL-6R at the cell surface. IL-6R is a non-signaling recep-
tor normally present only on hepatocytes and certain
leukocytes [50]. A homodimer of the signal-transducing
receptor gp130 is recruited to the IL-6-IL-6R complex,
followed by activation of Janus kinase (JAK) which is
recruited to the intracellular portion of gp130. JAK in
turns activates the transcription factor STAT3 (signal
transducer and activator of transcription) [48,51] by
phosphorylation. Phosphorylated STAT3 dimerizes and
travels to the nucleus, there initiating a transcriptional
program [50]. This program’s primary function is to
promote growth and differentiation and prevent apopto-
sis, and includes among others the induction of genes
encoding cyclin D1, survivin and Bcl-2 [52]. In addition,
STAT3 regulates genes that promote angiogenesis
through regulation of vascular endothelial growth factor
(VEGF) [53]. The IL-6 signal also activates the mitogen-
activated protein kinase (MAPK) pathway, specifically
extracellular signal-related kinase (ERK) through JAK
activation of SHP2 (a protein-tyrosine phosphatase),
which eventually activates the proto-oncogene Ras, a
GTPase found mutated in many human cancers [50],
especially in HCC [54]. In addition, IL-6 antagonizes
TGF-b-induced apoptosis in human hepatoma cell line
Hep3B [55], and this could be critical during cirrhosis
favoring the transformation of hepatocytes parallel to
the development of liver fibrosis. In addition, proinflam-
matory cytokines are part of the host response to
HCMV infection and participate in viral clearance. The
finding that HCMV seropositivity correlates with serum
IL-6 levels in HCC-/Cir+ patients and not in HCC+
patients suggest that IL-10 which is produced during
HCMV infection (vIL-10) does not impair the control of
Figure 4 Detection of HCMV DNA by nested PCR in the liver of HCC-positive patients. S: safe area, T: tumour area.
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proinflammatory cytokines such as IL-6 by infiltrating
lymphocytes in target organs. Our results are in accord
with the observation of Cheeran et al. [56], who
reported similar MCMV viral loads in IL-10 deficient
mice and in immunocompetent mice, C57BL/6 (which
i sam o d e ls i m u l a t e db yt h eI L - 1 0K Om i c er e p l e t e d
with mrIL-10).
HCMV is not an uncommon feature in patients with
liver diseases and may be a cause of systemic inflamma-
tion. Plasma cytokine interleukin-6 (IL-6) is mainly pro-
duced by circulating and peripheral cells and induces
the hepatic synthesis of C-reactive protein (CRP), which
is the main acute phase reactant. CRP expression in vivo
is assumed to be restricted mainly to the liver [57]
where CRP is produced under the control of various
proinflammatory cytokines such as interleukin 1 (IL-1),
IL-6 and tumor necrosis factor a (TNFa) [58]. Since IL-
6 has been reported to accompany HCMV replication
[12,13], IL-6 could favor CRP production in the liver of
HCMV-infected patients. Our results are in agreement
with this observation, since serum IL-6 correlated posi-
tively with that of CRP. Nevertheless, we cannot exclude
that CRP production is increased in these patients by
bacterial infections that could also favor IL-6
production.
To determine whether HCMV DNA was specifically
present in liver tumour area, we further performed a
nested PCR for HCMV UL82 (pp71) gene. Interestingly,
HCMV DNA was specifically detected in the tumour
area but not in safe area for one patient among 3 con-
sidered patients as previously described for glioma [34],
prostate cancers [36], colon cancers [35], and skin can-
cers [37]. However, HCMV DNA was either detected in
both tumour and safe areas or not detected for the
other two patients, indicating that the detection of
HCMV DNA in tumour area is not an invariant result
during hepatocellular carcinoma with our experimental
conditions. One limitation of this experiment might be
the use of fixed and paraffin embedded biopsies, as such
treatment was described to impair DNA [59]. Histologi-
cal evaluation of more liver biopsies might further be
considered to confirm these results.
Some limitations of the current study should be con-
sidered. First, the diagnosis of HCMV infection was
based on an indirect test and the absence of anti-
HCMV-IgG with the detection of HCMV DNA can
occur, especially in immunocompromised patients. Sec-
ond, the measurement of soluble receptor IL-6 might
have been helpful as an indirect marker of cell hepatic
responsiveness to IL-6 and therefore of CRP expression.
Third, the patients were characterized with only one
measurement of IL-6 and CRP.
Conclusions
Our results indicate that HCMV seroprevalence in
patients with HCC is significantly higher than in
patients without HCC and is positively correlated with
serum IL-6 levels in cirrhotic patients. If HCMV infec-
tion plays a significant role in the etiology of HCC, the
elimination of HCMV infection via the development and
administration of treatments or vaccines [60] may
reduce HCC mortality rates. Colugnati et al. predicted
that a vaccination against HCMV would not need to
have high efficacy nor wide-spread coverage to make a
substantial impact on HCMV transmission, and elimina-
tion of HCMV from the population has the potential to
greatly reduce the incidence of disease attributable to
HCMV infection [61]. Therefore, elimination of HCMV
infection is a potentially feasible and important avenue
of study for preventing diseases linked to HCMV infec-
tion. Future studies will be needed to further define the
role of HCMV in cancers including HCC.
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